Eisai’s NDA for Aricept tablets for treatment of Alzheimer’s disease accepted for review (News-Medical-Net)
Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai’s New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl extended release) tablets for the treatment of moderate to severe Alzheimer’s disease (AD).
Leave a Reply